A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3Β to phosphorylate cyclin D1 at Thr286, not Thr 288

Biochemical Journal

Volumn 457, Issue 1, 2014, Pages 43-56

  Ashford, Anne L ^a   Oxley, David ^a   Kettle, Jason ^b   Hudson, Kevin ^b   Guichard, Sylvie ^b   Cook, Simon J ^a   Lochhead, Pamela A ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

AZ191; Cell cycle; Cyclin D1; Dual specificity tyrosine phosphorylation regulated kinase 1B (DYRK1B); Glycogen synthase kinase 3 (GSK3 )

Indexed keywords

AZ 191; AZ 4216; CYCLIN D1; DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1B; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; THREONINE; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; EMBRYO; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION;

CELLS, CULTURED; CYCLIN D1; G1 PHASE CELL CYCLE CHECKPOINTS; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; PHOSPHORYLATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTEOLYSIS; PYRIMIDINES; SUBSTRATE SPECIFICITY; THREONINE;

EID: 84890011858     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20130461     Document Type: Article

References (45)

1. Becker, W. and Joost, H. G. (1999) Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. Prog. Nucleic Acid Res. Mol. Biol. 62, 1-17
2. Himpel, S., Panzer, P., Eirmbter, K., Czajkowska, H., Sayed, M., Packman, L. C., Blundell, T., Kentrup, H., Grotzinger, J., Joost, H. G. and Becker, W. (2001) Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. Biochem. J. 359, 497-505
3. Lochhead, P. A., Sibbet, G., Morrice, N. and Cleghon, V. (2005) Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs. Cell 121, 925-36
4. Becker, W., Weber, Y., Wetzel, K., Eirmbter, K., Tejedor, F. J. and Joost, H. G. (1998) Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases. J. Biol. Chem. 273, 25893-25902
5. Deng, X., Ewton, D. Z., Pawlikowski, B., Maimone, M. and Friedman, E. (2003) Mirk/dyrk1B is a Rho-induced kinase active in skeletal muscle differentiation. J. Biol. Chem. 278, 41347-41354
6. Leder, S., Weber, Y., Altafaj, X., Estivill, X., Joost, H. G. and Becker, W. (1999) Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases. Biochem. Biophys. Res. Commun. 254, 474-479
7. Kuuselo, R., Savinainen, K., Azorsa, D. O., Basu, G. D., Karhu, R., Tuzmen, S., Mousses, S. and Kallioniemi, A. (2007) Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification. Cancer Res. 67, 1943-1949
8. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I., Arthur, J. S., Alessi, D. R. and Cohen, P. (2007) The selectivity of protein kinase inhibitors: A further update. Biochem. J. 408, 297-315
9. Gockler, N., Jofre, G., Papadopoulos, C., Soppa, U., Tejedor, F. J. and Becker, W. (2009) Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J. 276, 6324-6337
10. Song, Y., Kesuma, D., Wang, J., Deng, Y., Duan, J., Wang, J. H. and Qi, R. Z. (2004) Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. Biochem. Biophys. Res. Commun. 317, 128-132
11. Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A. and Pestell, R. G. (1995) Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270, 23589-23597
12. Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J. and Kato, J. Y. (1994) D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14, 2066-2076
13. Diehl, J. A. (2002) Cycling to cancer with cyclin D1. Cancer Biol. Ther. 1, 226-231
14. Fukami-Kobayashi, J. and Mitsui, Y. (1999) Cyclin D1 inhibits cell proliferation through binding to PCNA and cdk2. Exp. Cell Res. 246, 338-347
15. Diehl, J. A., Cheng, M., Roussel, M. F. and Sherr, C. J. (1998) Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499-3511
16. Diehl, J. A., Zindy, F. and Sherr, C. J. (1997) Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11, 957-972
17. Alt, J. R., Cleveland, J. L., Hannink, M. and Diehl, J. A. (2000) Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 14, 3102-3114
18. Alao, J. P., Stavropoulou, A. V., Lam, E. W., Coombes, R. C. and Vigushin, D. M. (2006) Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol. Cancer 5, 8
19. Yang, K., Guo, Y., Stacey, W. C., Harwalkar, J., Fretthold, J., Hitomi, M. and Stacey, D. W. (2006) Glycogen synthase kinase 3 has a limited role in cell cycle regulation of cyclin D1 levels. BMC Cell Biol. 7, 33
20. Ewton, D. Z., Lee, K., Deng, X., Lim, S. and Friedman, E. (2003) Rapid turnover of cell-cycle regulators found in Mirk/dyrk1B transfectants. Int. J. Cancer 103, 21-28
21. Zou, Y., Ewton, D. Z., Deng, X., Mercer, S. E. and Friedman, E. (2004) Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J. Biol. Chem. 279, 27790-27798
22. Densham, R. M., Todd, D. E., Balmanno, K. and Cook, S. J. (2008) ERK1/2 and p38 cooperate to delay progression through G1 by promoting cyclin D1 protein turnover. Cell. Signalling 20, 1986-1994
23. Todd, D. E., Densham, R. M., Molton, S. A., Balmanno, K., Newson, C., Weston, C. R., Garner, A. P., Scott, L. and Cook, S. J. (2004) ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest. Oncogene 23, 3284-3295
24. Ley, R., Ewings, K. E., Hadfield, K., Howes, E., Balmanno, K. and Cook, S. J. (2004) Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J. Biol. Chem. 279, 8837-8847
25. Gilley, R., Lochhead, P. A., Balmanno, K., Oxley, D., Clark, J. and Cook, S. J. (2012) CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL. Cell. Signalling 24, 170-180
26. Wiggins, C. M., Tsvetkov, P., Johnson, M., Joyce, C. L., Lamb, C. A., Bryant, N. J., Komander, D., Komander, Y. and Cook, S. J. (2011) BIMEL, an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation. J. Cell Sci. 124, 969-977
27. Himpel, S., Tegge, W., Frank, R., Leder, S., Joost, H. G. and Becker, W. (2000) Specificity determinants of substrate recognition by the protein kinase DYRK1A. J. Biol. Chem. 275, 2431-2438
28. Yaffe, M. B., Schutkowski, M., Shen, M., Zhou, X. Z., Stukenberg, P. T., Rahfeld, J. U., Xu, J., Kuang, J., Kirschner, M. W., Fischer, G. et al. (1997) Sequence-specific and phosphorylation-dependent proline isomerization: A potential mitotic regulatory mechanism. Science 278, 1957-60
29. Lowe, E. D., Hasan, N., Trempe, J. F., Fonso, L., Noble, M. E., Endicott, J. A., Johnson, L. N. and Brown, N. R. (2006) Structures of the Dsk2 UBL and UBA domains and their complex. Acta Crystallogr., Sect. D: Biol. Crystallogr. 62, 177-188
30. Ring, D. B., Johnson, K. W., Henriksen, E. J., Nuss, J. M., Goff, D., Kinnick, T. R., Ma, S. T., Reeder, J. W., Samuels, I., Slabiak, T. et al. (2003) Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52, 588-595
31. Yost, C., Torres, M., Miller, J. R., Huang, E., Kimelman, D. and Moon, R. T. (1996) The axis-inducing activity, stability, and subcellular distribution of β-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10, 1443-1454
32. Baldin, V., Lukas, J., Marcote, M. J., Pagano, M. and Draetta, G. (1993) Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7, 812-821
33. Deng, X., Mercer, S. E., Shah, S., Ewton, D. Z. and Friedman, E. (2004) The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G0 by Mirk/dyrk1B kinase. J. Biol. Chem. 279, 22498-22504
34. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elledge, S. J. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816
35. Mercer, S. E., Ewton, D. Z., Deng, X., Deng, S., Deng, T. R. and Deng, E. (2005) Mirk/Dyrk1B mediates survival during the differentiation of C2C12 myoblasts. J. Biol. Chem. 280, 25788-25801
36. Polyak, K., Lee, M. H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P. and Massague, J. (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59-66
37. Ewton, D. Z., Hu, J., Vilenchik, M., Deng, X., Luk, K. C., Polonskaia, A., Hoffman, A. F., Zipf, K., Boylan, J. F. and Friedman, E. A. (2011) Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells. Mol. Cancer Ther. 10, 2104-2114
38. Hu, J., Deng, H. and Friedman, E. A. (2013) Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition. Int. J. Cancer 132, 2258-2269
39. Takahashi-Yanaga, F., Mori, J., Matsuzaki, E., Watanabe, Y., Hirata, M., Miwa, Y., Morimoto, S. and Sasaguri, T. (2006) Involvement of GSK-3β and DYRK1B in differentiation-inducing factor-3-induced phosphorylation of cyclin D1 in HeLa cells. J. Biol. Chem. 281, 38489-38497
40. Woods, Y. L., Cohen, P., Becker, W., Jakes, R., Goedert, M., Wang, X. and Proud, C. G. (2001) The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bε at Ser539 and the microtubule-associated protein tau at Thr212: Potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J. 355, 609-615
41. Skurat, A. V. and Dietrich, A. D. (2004) Phosphorylation of Ser640 in muscle glycogen synthase by DYRK family protein kinases. J. Biol. Chem. 279, 2490-2498
42. Jin, K., Ewton, D. Z., Park, S., Hu, J. and Friedman, E. (2009) Mirk regulates the exit of colon cancer cells from quiescence. J. Biol. Chem. 284, 22916-22925
43. Agami, R. and Bernards, R. (2000) Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 102, 55-66
44. Gao, J., Zheng, Z., Rawal, B., Schell, M. J., Bepler, G. and Haura, E. B. (2009) Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol. Ther. 8, 1671-1679
45. Deng, X., Ewton, D. Z. and Friedman, E. (2009) Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species. Cancer Res. 69, 3317-3324